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esponsibility of Xi'aAbstract Sanqi is a popular traditional Chinese medicine and commonly used for promoting blood
circulation and removing blood stasis. Notoginsenoside R1, ginsenoside Rg1, Re, Rb1 and Rd are the major
active constituents of Sanqi. The purpose of the study was to investigate the pharmacokinetic behavior of the
ﬁve active constituents from total saponin from Sanqi when it was used in the blood stasis animals or in
combination with Gegen. The concentrations of the ﬁve active constituents in rat plasma were determined by
an ultra-HPLC–ESI–MS/MS method. The main pharmacokinetic parameters were calculated and statistically
analyzed using the unpaired student's t-test. It was found that the pharmacokinetic parameters of
notoginsenoside R1, ginsenoside Rg1 and Rb1 represented a statistically signiﬁcant difference (Po0.05)
between the normal rats and the blood stasis rats after administration of total saponin from Sanqi (TSFS).
And there were statistically signiﬁcant differences (Po0.05) in the pharmacokinetic parameters of all the
ﬁve constituents between administration of TSFS alone and combined with total ﬂavonoid from Gegen
(TFFG) in blood stasis rats. It suggested that the pharmacokinetic behavior of the active constituents from
TSFS could be changed when it was used in blood stasis animals or in combination with TFFG.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.sity. Production and hosting by Elsev
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n Jiaotong University.1. Introduction
Sanqi, the roots of Panax notoginseng (Burk) F. H. Chen, is one of
the widely used traditional Chinese medicinal herbs (TCM) in
China for promoting blood circulation and removing blood stasis [1].
The dammarane-type saponins, are considered as the major activeier B.V. All rights reserved.
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skeleton, the saponins from Sanqi can be divided into two groups,
20 (S)—protopanaxadiol and 20 (S)—protopanaxatriol [2]. 20 (S)
—protopanaxadiol group saponins, such as ginsenoside Rb1, show
anti-inﬂammatory action, vasodilating effect and sedative effect on
central nervous system. 20 (S)—protopanaxatrial group saponins,
such as ginsenoside Rg1, possess the properties of exciting central
nervous system, anti-fatigue and hemolysis [3]. However, noto-
ginsenoside R1, ginsenoside Rg1, Rd, Re and Rb1 (Fig. 1(A)) are
regarded as the principal active constituents of Sanqi [4].
Hematological disorders such as thrombosis, hemorrhage, conges-
tion, local ischemia and tissue changes were considered to be related to
the blood stasis syndrome [5]. Blood stasis syndrome has the status of
platelet activation. As soon as blood stasis developed, the blood
circulation and the pharmacokinetic behavior of some active constitu-
ents will be affected [6,7]. Sanqi could inhibit platelet activation [4,8].
In recent years, some pharmacokinetic studies on the active constituents
from total saponin from Sanqi (TSFS) have been investigated [9–15].
However, few of them were investigated with the consideration of the
pathological condition [6,7]. Drug is used to treat diseases while patient
is the ultimate consumer of drug; therefore, it is necessary to study the
pharmacokinetics of TSFS in animals with blood stasis syndrome for
its rational clinical application. On the other hand, Sanqi is often used
in combination with Gegen in clinical application in order to obtain
synergistic effects and reduce possible side effect [16,17]. Gegen, the
roots of Pueraria lobata (Willd.) Ohwi, is another TCM which has
been proved effective for promoting blood circulation and removing
blood stasis [18]. Therefore, it is also important to perform the
pharmacokinetic studies to evaluate the rationality and compatibility
of combined treatment [19,20].
In this paper, an ultra-performance liquid chromatography–
tandem mass spectrometry (ultra-HPLC–MS/MS) method for the
simultaneous determination of notoginsenoside R1 and ginseno-
side Rg1, Re, Rb1 and Rd in rat plasma using digoxin as an
internal standard (IS, Fig. 1(B)) was developed and validated, and
applied to investigate the pharmacokinetic behavior of the ﬁve
active constituents from TSFS when it was used in the blood stasis
animals or in combination with Gegen.2. Materials and methods
2.1. Chemicals and reagents
The reference standards of notoginsenoside R1, ginsenoside Re,
ginsenoside Rd and digoxin were purchased from the NationalR1O
R3
OH
R2O
H
A B
Fig. 1 Chemical structures of notoginsenoside R1, ginsenosideInstitute for the Control of Pharmaceutical and Biological Products
(Beijing, China). Ginsenoside Rg1 and ginsenoside Rb1 were
purchased from Victory Bio-technology Company Limited
(Sichuan, China). Xuesaitong injection (consisting of 50.0 mg/mL
TSFS) was obtained from Yunnan Phytopharmaceutical Company
Limited (Yunnan, China). Total ﬂavonoid from Gegen (TFFG) was
obtained from Lvyuan Health-Care Products Company Limited
(Guangdong, China). Adrenaline hydrochloride injection was pro-
cured from Tianjin Jinyao Amino Acid Company Limited (Tianjin,
China). Acetonitrile and methanol of HPLC grade were purchased
from Fisher Scientiﬁc (Pittsburgh, PA, USA). Water was puriﬁed
by redistillation and passed through a 0.22 μm membrane ﬁlter
before use.
2.2. Animals
A total of 24 male Sprague-Dawley rats (200–240 g) with certiﬁcate
number SCXK 2010-0001 were obtained from the Experimental
Animal Center of Shenyang Pharmaceutical University (Shenyang,
China). They were kept in our laboratory for at least 3 days before
use and had access to the standard laboratory food and water ad
libitum. Animal experiments were carried out according to the
Guidelines for Animal Experimentation of Shenyang Pharmaceutical
University and the protocol of the study was approved by the
Animal Ethics Committee of this institution.
2.3. Preparation of solution for intravenous administration
The TSFS injection solution used in pharmacokinetic study was
prepared by diluting Xuesaitong injection to a concentration of
5.40 mg/mL with saline. The TFFG injection solution was
prepared as we reported previously [21]. The combined injection
consisted of 5.40 mg/mL TSFS and 16.4 mg/mL TFFG. Both the
injection solutions passed through a 0.22 μm membrane ﬁlter for
sterilization before use.
2.4. Preparation of standard solutions and quality control
samples
Stock solutions of notoginsenoside R1 (0.750 mg/mL), ginseno-
side Rg1 (1.97 mg/mL), Re (1.23 mg/mL), Rb1 (1.97 mg/mL) and
Rd (1.95 mg/mL) were separately prepared by dissolving the
reference substances in methanol:water (1:1, v/v). A series of
working solutions were prepared by diluting the stock solution
with methanol:water (1:1, v/v). Calibration curves were preparedO
OH
O O
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O
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O
3
Rg1, Re, Rb1 and Rd (A) and internal standard digoxin (B).
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obtain concentrations ranging from 0.050 to 5.00 μg/mL for
notoginsenoside R1, 0.10 to 10.0 μg/mL for ginsenoside Rg1,
0.050 to 5.00 μg/mL for ginsenoside Re, 0.20 to 50.0 μg/mL for
ginsenoside Rb1, and 0.20 to 10.0 μg/mL for ginsenoside Rd. The
IS solution was prepared at a concentration of 100 μg/mL in
methanol. All the solutions were stored at 4 1C and were brought
to room temperature before use. For the validation of the method,
four different concentration levels of quality control (QC) plasma
samples were prepared containing notoginsenoside R1 (0.10, 1.00,
4.00, and 20.0 μg/mL), ginsenoside Rg1 (0.20, 2.00, 8.00, and
40.0 μg/mL), ginsenoside Re (0.10, 1.00, 4.00, and 20.0 μg/mL),
ginsenoside Rb1 (0.50, 5.00, 40.0, and 200 μg/mL) and ginseno-
side Rd (0.50, 5.00, 8.00, and 40.0 μg/mL).
2.5. Method validation
The method was validated for selectivity, linearity, accuracy,
precision, recovery, matrix effect, dilution integrity and stability.
The selectivity of the method was validated by analyzing blank
rat plasma from six different rats, QC plasma samples and plasma
samples after drug administration.
The linearity of the method was validated by preparing different
concentrations of standard samples with blank plasma and assayed
in duplicate on three consecutive days. The lower limit of
quantitation (LLOQ) was deﬁned as the lowest concentration on
the calibration curve, in accordance with an accuracy within a 20%
deviation and a precision below 20%.
The accuracy and precision were calculated by determination of
QC plasma samples at three different concentrations on three
different validation days. The accuracy was expressed as the
relative error (RE) and the precision as the relative standard
deviation (RSD).
The extraction recoveries of analytes at three different concen-
trations were calculated by comparing the peak areas of the
extracted (pre-spiked) QC samples with those of the post-spiked
standard plasma samples at an equivalent concentration.
The matrix effects of analytes at three different concentrations
were determined by comparing the peak areas of the post-spiked
standard plasma samples with those of the neat standard samples at
an equivalent concentration.
The dilution integrity was investigated at 20.0 μg/mL for
notoginsenoside R1, 40.0 μg/mL for ginsenoside Rg1, 20.0 μg/
mL for ginsenoside Re, 200 μg/mL for ginsenoside Rb1 and
40.0 μg/mL for ginsenoside Rd of QC samples in order to validate
the dilution procedure. The plasma samples were prepared by 5-
fold dilution with blank plasma.
The stability of analytes in plasma was determined by using QC
plasma samples at three different concentrations in ﬁve replicates,
including (a) the long-term stability of the QC plasma samples at
−80 1C for 30 days, (b) the freeze-thaw stability of the QC plasma
samples after three freeze-thaw cycles (−80 1C to room tempera-
ture), (c) the stability of the fresh QC plasma samples at room
temperature for 4 h. The stability of the processed QC samples in
the sample injector at 10 1C for 12 h was carried out with the QC
samples used in the validation of intra-day precision.
2.6. Sample preparation
The 100 μL aliquot of plasma sample was spiked with 10 μL IS
(100 μg/mL) and 50 μL methanol:water (1:1, v/v) in a 1.5 mL EPtube. The mixture was vortexed for 30 s and 0.4 mL acetonitrile
was added, then vortexed for 3 min. After centrifugation at
15,000 rpm at 4 1C for 15 min, a certain volume of supernatant
was removed to another EP tube and evaporated to dryness under
nitrogen at 35 1C. The residue was reconstituted in 100 μL
incipient mobile phase, vortexed for 2 min and centrifuged at
15,000 rpm at 4 1C for 10 min. 5 μL aliquot of the supernatant was
injected into the ultra-HPLC–MS/MS system. The plasma sam-
ples, which concentrations were greater than the upper limit of the
calibration curve, could be re-analyzed by appropriate dilution.
2.7. Instrumentation and analytical conditions
Analyses were performed on a Waters Acquity™ UPLC system
(Waters Corp., Milford, MA, USA) coupled with a Micromass
Quattro Micro API mass spectrometer (Waters Corp., Milford,
MA, USA). Chromatographic separations were performed on a
Thermo Syncronis C18 column (10 cm 2.1 mm, 1.7 μm), main-
tained at 35 1C, with water (solvent A) and acetonitrile (solvent B)
as the mobile phase at a ﬂow rate of 250 μL/min. The gradient
elution program was as follows: 0–8 min, 19–35% B; 8–12 min,
35–65% B.
An electrospray ionization (ESI) source interface operated in the
positive ionization mode was used. Nitrogen was used as both
desolvation gas and cone gas, with a ﬂow rate of 50 L/h and
600 L/h, respectively. The desolvation and source temperatures
were set at 450 and 120 1C, respectively. The capillary voltage
was set at 3.2 kV. Argon was employed as the collision gas at a
pressure of approximately 0.3 Pa. Quantitation was performed
using time-dependent selected reaction monitoring (SRM) by the
[M+Na]+ molecular ions of the analytes. The corresponding
operational parameters are shown in Table 1. The full scan and
daughter scan mass spectra of notoginsenoside R1, ginsenoside
Rg1, Re, Rb1, Rd and IS are shown in Fig. 2.
2.8. In vivo pharmacokinetic study
The rats were randomly divided into the following three groups
(n¼8): Group I, normal rats administered of TSFS 27 mg/kg;
Group II, blood stasis model rats administered of TSFS 27 mg/kg;
Group III, blood stasis model rats administered of TSFS 27 mg/kg
combined with TFFG 82 mg/kg. The blood stasis model rats were
established as described by Tian et al. [7] with a little modiﬁcation:
the blood stasis rats were injected with adrenaline hydrochloride
injection (0.8 mg/kg). After waiting for 2 h, the rats were soaked in
ice-water for 5 min keeping their heads outside surface. Then,
those rats were injected with the same injection again after 2 h.
Rats were fasted for 12 h and administered via the caudal vein.
Blood samples (0.2 mL) were collected from the suborbital
veniplex and transferred to heparinized tubes at 0.033, 0.083,
0.167, 0.333, 0.667, 1.0, 1.5, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 h after
administration, and then centrifuged at 3500 rpm for 5 min to
obtain plasma. The plasma was frozen at −80 1C until analysis.
The plasma concentrations of notoginsenoside R1, ginsenoside
Rg1, Re, Rb1 and Rd at different time points were measured and
expressed as mean7standard deviation (SD), the mean concentra-
tion–time curve was plotted.
The pharmacokinetic parameters were calculated by a DAS
(Drug and Statistics for Windows) software package (version 2.1,
Chinese Pharmacological Society), relating to area under the
plasma concentration-time curve (AUC), clearance (CL), half-life
Fig. 2 MS and MS/MS spectra of notoginsenoside R1 (A), ginsenoside Rg1 (B), Re (C), Rb1 (D), Rd (E) and digoxin (F).
Table 1 Parameters of SRM mode used for determination.
Constituents m/z of precursor
ion (Da)
m/z of production
(Da)
Dwell time
(s)
Cone voltage
(eV)
Collision voltage
(eV)
Acquisition time
(min)
Notoginsenoside R1 955.9 775.7 0.5 65 55 4.5–5.5
Ginsenoside Rg1 823.8 643.5 0.5 62 42 5.0–6.5
Ginsenoside Re 969.8 789.6 0.5 60 48 5.0–6.5
Ginsenoside Rb1 1132.0 789.7 0.8 65 55 9.0–10.5
Ginsenoside Rd 969.9 789.6 0.8 65 55 10.0–11.0
Digoxin 803.7 803.7 0.5 60 15 8.5–9.5
X.-M. Liu et al.56(t1/2), mean residence time (MRT) and apparent volume of
distribution (Vd). The pharmacokinetic parameters were given as
mean7SD. The statistical analysis was performed with SPSS
Version 17.0 (SPSS Inc., Chicago, IL, USA) by the unpaired
Student's t-test. All statistical tests were performed at the two sided
5% level of signiﬁcance.
3. Results
3.1. Method validation
3.1.1. Selectivity
The typical chromatograms of notoginsenoside R1, ginsenoside Rg1,
Re, Rb1, Rd and IS are shown in Fig. 3. The retention times were 5.01,5.61, 5.68, 9.72, 10.57 and 9.24 min, respectively. The peak shapes
were good under the described conditions without interference peaks.
3.1.2. Linearity and LLOQ
The calibration curves were linear with correlation coefﬁcients (r)
exceeding 0.99. Regression equations and LLOQs for notoginse-
noside R1, ginsenoside Rg1, Re, Rb1 and Rd are listed in Table 2.
3.1.3. Precision and accuracy
The intra-day and inter-day precision and accuracy of notoginsenoside
R1, ginsenoside Rg1, Re, Rb1 and Rd at three different concentrations
are summarized in Table 3. The acceptance criteria for intra-day and
inter-day precision and accuracy are 15% for the QC concentrations.
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The extraction recoveries and matrix effects of notoginsenoside
R1, ginsenoside Rg1, Re, Rb1, Rd and IS are shown in Table 3.
These data indicated that the extraction recovery and matrix effect
of the method were acceptable.
3.1.5. Stability
The results of the stability data of QC samples study are
summarized in Table 4. It showed no signiﬁcant degradation
when QC samples were stored at −80 1C for 30 days, at −80 1C
for three freeze-thaw cycles (−80 1C to room temperature) and at
room temperature for 4 h. In addition, the processed samples in the
sample injector at 10 1C for 12 h were stable, and the accuracy
(RE, %) and precision (RSD, %) were within 10%.
3.1.6. Dilution integrity
For notoginsenoside R1, ginsenoside Rg1, Re, Rb1 and Rd, the
accuracy (RE) and precision (RSD) of the diluted QC samples
were in the range from −8.0% to 3.7% and 1.8% to 7.9%. The
results showed that it was appropriate to dilute the plasma samplesFig. 3 Typical chromatograms of blank plasma (A), blank plasma spiked
(B), and plasma sample obtained 1 h after intravenous administration of T
Table 2 Regression data and LLOQ for the ﬁve constituents determ
Constituents Regression equation Correlation co
Notoginsenoside R1 y¼0.02487x−0.0004 0.9950
Ginsenoside Rg1 y¼0.04590x−0.0017 0.9944
Ginsenoside Re y¼0.04011x+0.0002 0.9919
Ginsenoside Rb1 y¼0.02171x+0.0011 0.9991
Ginsenoside Rd y¼0.07144x+0.0059 0.9958when the plasma concentrations were greater than the upper limit
of the calibration curve for quantitation.3.2. Pharmacokinetic study
The validated method was successfully applied to the pharmaco-
kinetic study of notoginsenoside R1, ginsenoside Rg1, Re, Rb1
and Rd in rat plasma after intravenous administration of TSFS and
TSFS combined with TFFG. The mean plasma concentration–time
curves are illustrated in Figs. 4 and 5, respectively. The main
pharmacokinetic parameters of the ﬁve constituents including
AUC0–n, MRT0–t, t1/2, CL, and, Vd are presented in Tables 5–9.
There were statistically signiﬁcant differences (Po0.05) in the
pharmacokinetic parameters of notoginsenoside R1, ginsenoside
Rg1 and Rb1 between Group I and Group II, which were both
administered of TSFS alone. In comparison with Group I, the
AUC0–t of notoginsenoside R1 and ginsenoside Rg1 in the blood
stasis rats were remarkably increased (Po0.05), the t1/2 values
were increased (Po0.05), the CL values were decreased
(Po0.05), on the contrary, the AUC0–t of ginsenoside Rb1 waswith notoginsenoside R1, ginsenoside Rg1, Rd, Re, Rb1 and digoxin
SFS combined with TFFG (C).
ined.
efﬁcient (r) Linear range (μg/mL) LLOQ (μg/mL)
0.050–5.00 0.050
0.10–10.0 0.10
0.050–5.00 0.050
0.20–50.0 0.20
0.20–10.0 0.20
Table 3 Precision, accuracy, extraction recovery and matrix effect of the ﬁve constituents determined in rat plasma.
Constituents and concentration (μg/mL) Intra-day Inter-day Extraction recovery Matrix effect
Precision
(RSD, %)
Accuracy
(RE, %)
Precision
(RSD, %)
Accuracy
(RE, %)
Mean
(%)
RSD
(%)
Mean
(%)
RSD
(%)
Notoginsenoside R1
0.10 4.2 −6.8 6.3 −4.8 90.6 4.2 96.8 3.1
1.00 3.6 −3.8 2.7 −2.6 80.5 6.5 95.6 6.5
4.00 5.8 −1.9 0.9 −1.6 83.7 4.0 97.6 1.6
Ginsenoside Rg1
0.20 3.2 2.2 3.2 1.0 93.1 3.7 94.0 2.6
2.00 5.6 3.7 3.8 2.1 88.0 3.3 88.6 5.7
8.00 5.4 0.2 1.3 0.5 93.4 1.0 90.8 1.8
Ginsenoside Re
0.10 3.6 9.0 2.3 3.6 89.8 4.7 93.1 3.1
1.00 4.3 2.3 2.3 1.6 87.3 7.1 89.2 7.0
4.00 5.7 −1.4 1.4 −0.8 93.6 1.3 91.2 1.3
Ginsenoside Rb1
0.50 4.2 −5.1 5.7 −3.1 90.5 3.6 96.2 6.0
5.00 5.4 −4.9 4.1 −3.4 91.7 6.6 102.4 9.8
40.0 3.9 −4.3 7.2 −1.1 86.6 4.4 90.7 5.4
Ginsenoside Rd
0.50 3.8 −3.7 3.2 −2.8 85.1 3.6 92.6 6.2
5.00 5.0 −3.5 3.1 −2.1 86.7 5.7 96.9 3.8
8.00 3.9 0.6 1.0 0.2 86.7 5.2 90.7 8.2
Digoxin (I.S.)
10.00 – – – – 90.2 5.8 98.9 3.9
Table 4 The stability of the ﬁve constituents in plasma sample (n¼5).
Constituents and concentration (μg/mL) Frozen for 30 days Three freeze-thaw cycles Room temperature for 4 h
Precision
(RSD, %)
Accuracy
(RE, %)
Precision
(RSD, %)
Accuracy
(RE, %)
Precision
(RSD, %)
Accuracy
(RE, %)
Notoginsenoside R1
0.10 1.0 −8.4 5.0 −2.9 5.7 −1.9
4.00 4.9 −0.7 2.9 −1.7 6.8 −1.0
20.0 7.1 −0.5 2.9 −2.2 7.2 −0.5
Ginsenoside Rg1
0.20 1.0 −1.2 10.0 0.1 4.8 4.7
8.00 6.0 −0.9 7.0 −0.4 4.8 −0.1
40.0 11.4 −0.7 5.9 −0.7 6.4 −0.1
Ginsenoside Re
0.10 4.4 −1.0 4.3 −0.6 3.8 −1.5
4.00 6.3 −2.1 6.1 −0.2 5.6 −0.8
20.0 6.6 −2.3 5.0 −1.4 4.9 −1.4
Ginsenoside Rb1
0.50 5.6 −3.8 2.1 −6.2 4.3 0.8
40.0 3.2 3.8 4.3 5.9 1.9 5.6
200 6.3 1.1 8.3 2.3 8.0 2.8
Ginsenoside Rd
0.50 2.8 −4.9 4.6 −1.4 6.1 −0.8
8.00 4.7 −0.4 2.9 −2.2 5.6 −4.0
40.0 4.3 −1.3 4.4 −0.1 2.7 −3.2
X.-M. Liu et al.58remarkably decreased (Po0.05), the CL was increased (Po0.05).
There were no statistically signiﬁcant differences in the pharma-
cokinetic parameters of ginsenoside Re and Rd between the two
groups mentioned above.There were statistically signiﬁcant differences (Po0.05) in the
pharmacokinetic parameters of all the ﬁve constituents between
Group II and Group III. In comparison with Group II, the AUC0–t
values of notoginsenoside R1 and ginsenoside Rg1 in Group III
Fig. 4 Plasma concentration–time curves of notoginsenoside R1, ginsenoside Rg1, Rd, Re and Rb1 after intravenous administration of TSFS in
normal rats (Group I) and blood stasis rats (Group II).
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increased (Po0.05), on the contrary, the AUC0–t values of
ginsenoside Re, Rb1 and Rd were remarkably increased
(Po0.05) and the CL values were decreased (Po0.05).4. Discussion
4.1. Method development
4.1.1. Optimization of LC–MS/MS conditions
The reference standards of the ﬁve constituents and IS were
analyzed by direct injection to optimize the MS/MS conditions.
The MS spectra of the ﬁve constituents and IS were investigated in
both positive and negative ion modes. In the positive full scan
mode, the ﬁve constituents and IS could form adduct ions of
[M+Na]+. Although the ﬁve constituents and IS could form stable
de-protonated ions of [M−H]− in the negative full scan mode, the
response in positive mode was much higher than that in negative
mode. Therefore, we selected [M+Na]+ in the positive full scan
mode as the precursor ions for SRM detection of the ﬁve
constituents and IS. The MS parameters were optimized according
to the MS responses of the ﬁve constituents and IS. The product
ion spectra of the ﬁve constituents and IS were produced using
argon as collision gas, and the collision energy was optimized for a
stable response and highest intensity as shown in Table 1. It was
found that acetonitrile produced better resolution and peak shapes
than methanol. When a small amount (0.05%, 0.1% and 0.5%) of
acid (formic acid or acetic acid) was added into the mobile phase,
the MS responses did not change signiﬁcantly. Therefore, we
selected water–acetontrile as the mobile phase. In order to separate
the analytes completely from the endogenous substances and
reduce the matrix effect, a gradient elution mode was applied forthe separation and simultaneous determination of the ﬁve con-
stituents and IS in rat plasma samples.
4.1.2. Optimization of sample preparation
Protein precipitation and liquid–liquid extraction were investigated
in order to extract the ﬁve constituents and IS from plasma.
However, the liquid–liquid extraction with ethyl acetate or
n-butanol showed limited extraction recovery efﬁciency of the
analytes. So protein precipitation was ﬁnally selected. Different
precipitation organic solvents (methanol, acetonitrile or acetone)
were evaluated in order to improve the extraction recovery
efﬁciency of the analytes and IS. Acetonitrile was ﬁnally selected
because of its high extraction recovery efﬁciency and perfect
peak shape.
4.2. Pharmacokinetic parameters
An ultra-HPLC–ESI–MS/MS method had been developed and
validated for determination of notoginsenoside R1, ginseno-
side Rg1, Re, Rb1 and Rd after administration of TSFS alone
and TSFS combined with TFFG in rats under different
physiological states. In comparison with the normal rats, the
blood stasis rats had a signiﬁcant extension of the half-life
time and MRT0−t (Po0.05), and increase in the AUC
(po0.05) of notoginsenoside R1 and ginsenoside Rg1 after
administration of TSFS. The following reasons may explain
why the pharmacokinetic parameters change. The blood
circulation of the blood stasis rats will be sluggish, leading
to the increase of whole blood viscosity, plasma viscosity,
ﬁbrinogen and hematocrit [7]. Notoginsenoside R1 and ginse-
noside Rg1 (20(S)-protopanaxatriol) were absorbed rapidly
into plasma and metabolized quickly, so the poor blood
Table 5 Pharmacokinetic parameters of notoginsenoside R1 in three group rats after intravenous administration of drugs (n¼6).
Parameter Group I Group II Group III
AUC(0-t) (μg h/mL) 2.9970.43 6.4171.36* 3.2570.47Δ
AUC(0-∞) (μg h/mL) 3.1870.52 6.8671.41* 3.3670.54Δ
MRT(0-t) (h) 0.5170.04 1.0870.13
* 0.9470.11
t1/2 (h) 0.5070.13 1.0370.23
* 0.8070.14
CL (L/h/kg) 0.7570.14 0.3570.08* 0.7070.10Δ
Vd (L/kg) 0.5370.09 0.5270.14 0.8070.08Δ
Data represent Mean7SD. Group I, normal rats administered of TSFS 27 mg/kg; Group II, blood stasis model rats administered of TSFS 27 mg/kg;
Group III, blood stasis model rats administered of TSFS 27 mg/kg combined with TFFG 82 mg/kg.
nPo0.05, compared with normal rats.
ΔPo0.05, compared with acute blood stasis rats administered with TSFS.
Fig. 5 Plasma concentration–time curves of notoginsenoside R1, ginsenoside Rg1, Rd, Re and Rb1 after intravenous administration of TSFS
alone (Group II) and TSFS combined with TFFG in blood stasis rats (Group III).
X.-M. Liu et al.60circulation was more likely to inﬂuence the pharmacokinetic
behavior of the two constituents. Meanwhile, in blood stasis
rats, the elimination of ginsenoside Rb1 (20(S)-protopanax-
adiol) from rat plasma was rapid in comparison with normal
rats. It was noticed that the blood stasis rats need the supply of
ginsenoside Rb1 to remove the blood stasis. It is coincident
with the anti-platelet aggregation effect of ginsenoside Rb1
[22]. On the other hand, the major metabolic pathways of
saponins in rat were found to be oxygenation and deglycosyla-
tion, which were catalyzed mainly by enzymes in rat liver [23].
Tian et al. [7] reported that the blood stasis syndrome had
effect on rat liver cytochrome P450-catalyzed drug metabo-
lism, owing to this reason, blood stasis syndrome will have
effect on the pharmacokinetic behavior of some saponins
from Sanqi.The interaction between TSFS and TFFG was further investi-
gated by comparing the pharmacokinetic parameters after admin-
istration of TSFS alone and TSFS combined with TFFG in blood
stasis rats. Blood stasis rat has the status of platelet activation,
which is a complex and multifactor process, including platelet
adhesion, aggregation and reaction release. TSFS and TFFG have
common mechanisms of inhibiting platelet activation [24]. Mean-
while, there are some differences in metabolic pathway due to the
complexity of the constituents in TSFS and TFFG. The major
metabolic pathways of saponins in TSFS were found to be
oxygenation and deglycosylation [23], while the ﬂavonoids C-
glycosides in TFFG such as puerarin were glucurnidation and
sulfation [25]. Therefore, there were limited competitive metabo-
lism and excretion between TSFS and TFFG. In comparison
with administration of TSFS alone, the AUC (Po0.05) of
Table 7 Pharmacokinetic parameters of ginsenoside Re in three group rats after intravenous administration of drugs (n¼6).
Parameter Group I Group II Group III
AUC(0-t) (μg h/mL) 1.4270.35 1.3270.31 1.9870.45Δ
AUC(0-∞) (μg h/mL) 1.4870.42 1.3770.37 2.1170.51Δ
MRT(0-t) (h) 0.4070.10 0.4170.09 0.6770.18
Δ
t1/2 (h) 0.4270.14 0.4270.15 0.6870.22
Δ
CL (L/h/kg) 0.8470.25 0.9070.25 0.5870.14Δ
Vd (L/kg) 0.4770.05 0.5070.08 0.5470.09
Data represent Mean7SD. Group I, normal rats administered of TSFS 27 mg/kg; Group II, blood stasis model rats administered of TSFS 27 mg/kg;
Group III, blood stasis model rats administered of TSFS 27 mg/kg combined with TFFG 82 mg/kg.
nPo0.05, compared with normal rats.
ΔPo0.05, compared with acute blood stasis rats administered with TSFS.
Table 8 Pharmacokinetic parameters of ginsenoside Rb1 in three group rats after intravenous administration of drugs (n¼6).
Parameter Group I Group II Group III
AUC(0-t) (μg h/mL) 1906.77169.6 1547.47142.9* 1936.97212.0Δ
AUC(0-∞) (μg h/mL) 1953.47178.9 1606.07131.0* 1986.57228.2Δ
MRT(0-t) (h) 22.9471.21 24.8071.34
* 22.5971.48Δ
t1/2 (h) 17.3371.88 19.6773.88 17.9671.62
CL (L/h/kg) 0.00570.001 0.00670.001* 0.00570.001Δ
Vd (L/kg) 0.1270.01 0.1770.04* 0.1270.01Δ
Data represent Mean7SD. Group I, normal rats administered of TSFS 27 mg/kg; Group II, blood stasis model rats administered of TSFS 27 mg/kg;
Group III, blood stasis model rats administered of TSFS 27 mg/kg combined with TFFG 82 mg/kg.
nPo0.05, compared with normal rats.
ΔPo0.05, compared with acute blood stasis rats administered with TSFS.
Table 6 Pharmacokinetic parameters of ginsenoside Rg1 in three group rats after intravenous administration of drugs (n¼6).
Parameter Group I Group II Group III
AUC(0-t) (μg h/mL) 11.6272.14 15.9972.84* 12.5171.76Δ
AUC(0-∞) (μg h/mL) 12.0072.34 16.3972.98* 12.9672.10Δ
MRT(0-t) (h) 0.4470.08 0.7470.14
* 0.6370.11Δ
t1/2 (h) 0.4070.08 0.7470.22
* 0.6270.18
CL (L/h/kg) 0.7370.16 0.5370.11* 0.6670.11
Vd (L/kg) 0.4170.08 0.5670.14 0.6170.12
Data represent Mean7SD. Group I, normal rats administered of TSFS 27 mg/kg; Group II, blood stasis model rats administered of TSFS 27 mg/kg;
Group III, blood stasis model rats administered of TSFS 27 mg/kg combined with TFFG 82 mg/kg.
nPo0.05, compared with normal rats.
Δ
Po0.05, compared with acute blood stasis rats administered with TSFS.
Pharmacokinetics of ﬁve saponins in normal and blood stasis rats 61notoginsenoside R1 and ginsenoside Rg1 decreased after admin-
istration of TSFS combined with TFFG. It indicated that admin-
istration of TSFS combined with TFFG in blood stasis rats would
effectively promote the blood circulation, leading to the elimina-
tion of notoginsenoside R1 and ginsenoside Rg1 faster than that of
TSFS alone. The differences in the AUC of ginsenoside Re, Rb1
and Rd in blood stasis rats were signiﬁcant between TSFS alone
and TFSF combined with TFFG. It could be inferred that TFFG
might have effects on the absorption and bioavailability of
ginsenoside Re, Rb1 and Rd in blood stasis rats: the elimination
stepped down and AUC increased, which might have a synergistic
effect on anti-platelet activation.5. Conclusion
A simple and validated ultra-HPLC–MS/MS method was devel-
oped for the determination of notoginsenoside R1, ginsenoside
Rg1, Re, Rb1 and Rd in rat plasma. The method was then
successfully applied to the pharmacokinetic comparisons of noto-
ginsenoside R1, ginsenoside Rg1, Re, Rb1 and Rd in normal rats
after intravenous administration of TSFS and in blood stasis rats after
intravenous administration of TSFS alone and TSFS combined with
TFFG. The results suggested that the pharmacokinetic behavior of the
active constituents from TSFS could be changed when it was used in
the blood stasis animals or in combination with TFFG. The results are
Table 9 Pharmacokinetic parameters of ginsenoside Rd in three group rats after intravenous administration of drugs (n¼6).
Parameter Group I Group II Group III
AUC(0-t) (μg h/mL) 260.0750.7 248.7749.2 315.7741.0Δ
AUC(0-∞) (μg h/mL) 298.0776.7 271.5748.2 360.5776.8Δ
MRT(0-t) (h) 26.4273.30 25.8071.63 26.6873.90
t1/2 (h) 31.7579.44 29.7479.55 31.87712.30
CL (L/h/kg) 0.00870.003 0.00970.001 0.00670.001Δ
Vd (L/kg) 0.3470.06 0.3770.17 0.2870.06
Data represent Mean7SD. Group I, normal rats administered of TSFS 27 mg/kg; Group II, blood stasis model rats administered of TSFS 27 mg/kg;
Group III, blood stasis model rats administered of TSFS 27 mg/kg combined with TFFG 82 mg/kg.
* Po0.05, compared with normal rats.
ΔPo0.05, compared with acute blood stasis rats administered with TSFS.
X.-M. Liu et al.62useful for the further study of the rational clinical application of
TSFS.
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